Adaptimmune Therapeutics (ADAP) Plans Offering of ADSs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Adaptimmune Therapeutics (ADAP) Prices 21 Million Offering at $4/ADS
January 22, 2020 8:49 AM ESTAdaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (ADSs) at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune... More
